Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib vs Sorafenib Maintenance in FLT3-ITD+ AML Post-Transplant
NCT07463651Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Measurable residual disease recurrence-free survival at 2 years. Started May 2026; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07463651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463651.